| Literature DB >> 34505213 |
Julie Katrine Karstensen1,2,3,4, Jette Primdahl5,6,7, Maria L E Andersson8,9, Jeanette Reffstrup Christensen10,11, Ann Bremander5,6,8,9.
Abstract
INTRODUCTION: The risk for cardiovascular diseases and other comorbidities increases with the number of unhealthy lifestyle factors in the general population. However, information on the combined number of unhealthy lifestyle factors in people with rheumatoid arthritis (RA) is scarce.Entities:
Keywords: Cardiovascular risk; Health behaviour; Lifestyle habits; Rheumatic diseases
Mesh:
Year: 2021 PMID: 34505213 PMCID: PMC8782815 DOI: 10.1007/s10067-021-05905-2
Source DB: PubMed Journal: Clin Rheumatol ISSN: 0770-3198 Impact factor: 2.980
General characteristics of the Danish cohort
| All | Men | Women | ||||
|---|---|---|---|---|---|---|
| Age, years | 566 | 61.82 (11.13) | 64.20 (10.00) | 60.90 (11.42) | ||
| Disease duration, years | 561 | 12.40 (10.95) | 10.61 (10.80) | 13.04 (10.95) | ||
| Positive RF | 340 | 249 (73.2) | 65 (69.9) | 184 (74.5) | ||
| DAS28-CRP | 443 | 2.46 (1.10) | 2.39 (1.05) | 2.48 (1.10) | ||
| TJC | 460 | 1.70 (3.61) | 1.40 (3.30) | 1.81 (3.73) | ||
| SJC | 459 | 0.51 (1.52) | 0.55 (1.60) | 0.50 (1.50) | ||
| PatGa | 547 | 34.13 (27.30) | 31.72 (25.99) | 35.08 (27.80) | ||
| Pain | 542 | 31.33 (24.54) | 29.62 (24.04) | 32.01 (24.73) | ||
| Fatigue | 547 | 38.91 (28.05) | 34.20 (26.90) | 40.80 (28.30) | ||
| HAQ | 540 | 0.66 (0.62) | 0.45 (0.52) | 0.75 (0.64) | ||
| EQ5D | 459 | 0.78 (0.17) | 0.80 (0.17) | 0.78 (0.16) | ||
| Cardiovascular disease*1 | 566 | 233 (41.2) | 79 (49.7) | 154 (37.8) | ||
| Pulmonary disease*2 | 0 | 0 | 0 | 0 | ||
| Medical treatment | ||||||
| No DMARD or CS | 532 | 0 | 0 | 0 | ||
| cDMARD ± CS | 532 | 372 (70.0) | 118 (76.6) | 254 (67.2) | ||
| bDMARD ± CS | 532 | 155 (29.1) | 35 (22.7) | 120 (31.7) | ||
| Only CS | 532 | 5 (0.9) | 1 (0.7) | 4 (1.1) | ||
| Lifestyle factors | ||||||
| Tobacco use | 566 | 125 (22.1) | 39 (24.5) | 86 (21.1) | ||
| BMI, kg/m2 | 566 | 27.44 (5.70) | 27.70 (4.80) | 27.35 (6.00) | ||
| BMI, kg/m2 | < 25.0 | 566 | 209 (36.9) | 49 (30.8) | 160 (39.3) | |
| BMI, kg/m2 | 25.0–29.9 | 566 | 191 (33.7) | 63 (39.6) | 128 (30.4) | |
| BMI, kg/m2 | ≥ 30 | 566 | 166 (29.3) | 47 (29.6) | 119 (29.2) | |
| Alcohol above national limits*3 | 566 | 35 (6.2) | 9 (5.6) | 26 (6.4) | ||
| Physical activity < 150 min/week (MVPA) | 566 | 478 (84.4) | 136 (85.5) | 342 (84.0) | ||
Data presented as mean (SD) or n (%)
RF, rheumatoid factor; DAS28–CRP, disease activity score in 28 joints–CRP and patient global assessment score (0–10); TJC, tender joint count (0–28); SJC, swollen joint count (0–28); PatGa, patient global assessment (0–100, best to worst); pain (0–100, best to worst); fatigue (0–100, best to worst); HAQ, Health Assessment Questionnaire (0–3, best to worst); EQ5D, Euroqol Five Dimensions (0–1, worst to best); cDMARD, conventional disease-modifying antirheumatic drugs (with or without corticosteroids); bDMARD, biological disease-modifying antirheumatic drugs (with or without corticosteroids); CS, corticosteroids; BMI, body mass index
*1Includes hypertension, hypercholesterolemia, angina pectoris, myocardial infarction, stroke, vasoconstriction of the legs and ‘other CVDs’
*2Includes asthma, chronic bronchitis and tuberculosis
*3Max. 7 units/week for women and 14 for men
General characteristics of the Swedish cohort
| All | Men | Women | ||||
|---|---|---|---|---|---|---|
| Age, years | 955 | 66.38 (12.90) | 69.39 (12.13) | 65.27 (13.00) | ||
| Disease duration, years | 955 | 15.55 (3.85) | 15.72 (3.90) | 15.48 (3.84) | ||
| RF pos | 939 | 622 (65.1) | 174 (67.2) | 448 (64.4) | ||
| TJC | 955 | 5.20 (6.60) | 4.36 (6.20) | 5.51 (6.70) | ||
| SJC | 955 | 3.06 (4.90) | 2.53 (4.72) | 3.26 (4.94) | ||
| PatGa | 955 | 3.04 (2.43) | 2.82 (2.35) | 3.12 (2.50) | ||
| Pain | 923 | 3.42 (2.54) | 2.94 (2.50) | 3.60 (2.54) | ||
| Fatigue | 927 | 4.08 (2.85) | 3.40 (2.63) | 4.33 (2.90) | ||
| HAQ | 945 | 0.52 (0.55) | 0.41 (0.53) | 0.56 (0.56) | ||
| EQ5D | 921 | 0.72 (0.25) | 0.77 (0.21) | 0.70 (0.25) | ||
| Cardiovascular disease*1 | 934 | 471 (49.3) | 148 (57.1) | 323 (46.4) | ||
| Pulmonary disease*2 | 919 | 113 (11.8) | 35 (13.5) | 78 (11.2) | ||
| Medical treatment | ||||||
| No DMARD or CS | 884 | 146 (15.3) | 35 (13.5) | 111 (15.9) | ||
| cDMARD ± CS | 884 | 387 (40.5) | 109 (42.1) | 278 (39.9) | ||
| bDMARD ± CS | 884 | 293 (30.7) | 66 (25.5) | 227 (32.6) | ||
| Only CS | 884 | 58 (6.1) | 23 (8.9) | 35 (5.0) | ||
| Lifestyle factors | ||||||
| Tobacco use | 955 | 163 (17.1) | 63 (24.3) | 100 (14.4) | ||
| BMI, kg/m2 | 955 | 25.93 (4.73) | 26.25 (3.62) | 25.81 (5.10) | ||
| BMI, kg/m2 | < 25.0 | 955 | 444 (46.5) | 99 (38.2) | 345 (49.6) | |
| BMI, kg/m2 | 25.0–29.9 | 955 | 357 (37.4) | 125 (48.3) | 232 (33.3) | |
| BMI, kg/m2 | ≥ 30 | 955 | 154 (16.1) | 35 (13.5) | 119 (17.1) | |
| Alcohol above national limits*3 | 955 | 185 (19.4) | 52 (20.1) | 133 (19.1) | ||
| Physical activity < 150 min/week (MVPA) | 955 | 492 (51.5) | 134 (51.7) | 358 (51.4) | ||
Data presented as mean (SD) or n (%)
RF, rheumatoid factor; TJC, tender joint count (0–28); SJC, swollen joint count (0–28); PatGa, patient global assessment (0–10, best to worst); pain (0–10, best to worst); fatigue (0–10, best to worst); HAQ, Health Assessment Questionnaire (0–3, best to worst); EQ5D, Euroqol Five Dimensions (0–1, worst to best); cDMARD, conventional disease-modifying antirheumatic drugs (with or without corticosteroids); bDMARD, biological disease-modifying antirheumatic drugs (with or without corticosteroids); CS, corticosteroids; BMI, body mass index
*1Includes hypertension, hypercholesterolemia, angina pectoris, myocardial infarction, thrombosis and stroke
*2Includes asthma, chronic obstructive pulmonary disease and emphysema
*3AUDIT-C > 4 points for women and > 5 points for men
Number of unhealthy lifestyle factors (0–4) in the Danish cohort (N = 566)
| 0 | 1 | 2 | 3 | 4 | ||
|---|---|---|---|---|---|---|
| Age, years | 63.93 (8.86) | 62.10 (12.05) | 61.87 (11.23) | 60.42 (9.37) | 59.60 (10.60) | 0.63 |
| Gender, women/men | 73.3/26.6 | 81.6/18.4 | 66/34 | 72.2/27.8 | 85.7/14.3 | 0.008 |
| Disease duration, years | 14.63 (12.01) | 15.03 (13.53) | 11.45 (9.32) | 8.99 (8.53) | 13.14 (11.51) | < 0.001 |
| TJC | 1.48 (4.20) | 1.60 (3.30) | 1.71 (3.60) | 1.80 (4.23) | 2.83 (4.20) | 0.93 |
| SJC | 0.52 (1.83) | 0.60 (1.50) | 0.50 (1.63) | 0.40 (1.01) | 0.50 (0.84) | 0.96 |
| PatGA | 31.87 (24.86) | 33.64 (27.10) | 34.23 (27.30) | 35.60 (29.62) | 36.71 (25.70) | 0.97 |
| Pain | 30.73 (25.87) | 31.70 (24.04) | 30.92 (24.35) | 32.30 (26.23) | 33.14 (27.30) | 0.99 |
| Fatigue | 33.70 (25.94) | 38.20 (26.96) | 38.80 (28.60) | 42.90 (29.80) | 42.90 (21.90) | 0.61 |
| HAQ | 0.57 (0.52) | 0.65 (0.62) | 0.68 (0.63) | 0.68 (0.63) | 0.54 (0.51) | 0.88 |
| EQ5D | 0.78 (0.15) | 0.80 (0.18) | 0.77 (0.16) | 0.77 (0.17) | 0.80 (0.15) | 0.80 |
| Cardiovascular disease*1 | 43.3 | 29.4 | 48 | 39 | 43 | 0.003 |
| Pulmonary disease*2 | 0 | 0 | 0 | 0 | 0 | na |
Data presented as mean (SD) or %
TJC, tender joint count (0–28); SJC, swollen joint count (0–28); PatGa, patient global assessment (0–100, best to worst); pain (0–100, best to worst); fatigue (0–100, best to worst); HAQ, Health Assessment Questionnaire (0–3, best to worst); EQ5D, Euroqol Five Dimensions (0–1, worst to best)
*1Includes hypertension, hypercholesterolemia, angina pectoris, myocardial infarction, stroke, vasoconstriction of the legs and ‘other CVDs’
*2Includes chronic bronchitis, asthma and tuberculosis
*3ANCOVA or Fisher’s exact test
Number of unhealthy lifestyle factors (0–4) in the Swedish cohort (N = 955)
| 0 | 1 | 2 | 3 | 4 | ||
|---|---|---|---|---|---|---|
| Age, years | 63.97 (14.60) | 66.59 (13.34) | 68.29 (11.90) | 63.25 (10.80) | 70.70 (5.90) | 0.000 |
| Gender, women/men | 77.3/22.7 | 75.5/24.5 | 72.7/27.3 | 59.6/40.4 | 50/50 | 0.005 |
| Disease duration, years | 15.78 (3.99) | 15.52 (3.83) | 15.57 (3.82) | 15.34 (3.86) | 13.80 (2.53) | 0.547 |
| TJC | 4.65 (5.90) | 5.21 (6.60) | 5.36 (6.80) | 5.54 (7.03) | 5.30 (6.24) | 0.795 |
| SJC | 2.47 (3.84) | 2.88 (4.90) | 3.50 (5.30) | 3.42 (5.36) | 1.50 (2.10) | 0.125 |
| PatGA | 2.74 (2.32) | 2.88 (2.40) | 3.29 (2.50) | 3.26 (2.50) | 3.00 (1.83) | 0.077 |
| Pain | 3.05 (2.50) | 3.24 (2.44) | 3.74 (2.63) | 3.61 (2.64) | 3.44 (2.01) | 0.026 |
| Fatigue | 3.60 (2.90) | 3.89 (2.82) | 4.44 (2.90) | 4.36 (2.74) | 4.22 (2.90) | 0.014 |
| HAQ | 0.36 (0.41) | 0.50 (0.54) | 0.60 (0.62) | 0.57 (0.55) | 0.54 (0.42) | 0.000 |
| EQ5D | 0.77 (0.20) | 0.73 (0.233) | 0.68 (0.27) | 0.69 (0.27) | 0.76 (0.9) | 0.001 |
| Cardiovascular disease*1 | 36.6 | 47.1 | 59.7 | 53.4 | 70 | 0.000 |
| Pulmonary disease*2 | 5.3 | 13.5 | 12.9 | 18.4 | 11.1 | 0.018 |
Data presented as mean (SD) or %
TJC, tender joint count (0–28); SJC, swollen joint count (0–28); PatGa, patient global assessment (0–10, best to worst); pain (0–10, best to worst); fatigue (0–10, best to worst); HAQ, Health Assessment Questionnaire (0–3, best to worst); EQ5D, Euroqol Five Dimensions (0–1, worst to best)
*1Includes hypertension, hypercholesterolemia, angina pectoris, myocardial infarction, thrombosis and stroke
*2Includes asthma, chronic obstructive pulmonary disease and emphysema
*3ANCOVA or Chi2
Associations between the combined number of unhealthy lifestyle factors (UL) and disease-related factors among the Danish patients (N = 566)
| < 2 UL | ≥ 2 UL | OR† (CI 95%) | ||
|---|---|---|---|---|
| Age | 62.35 (11.61) | 61.54 (10.90) | 0.99 (0.98–1.01) | 0.75 |
| Gender, men | 38 (19.7) | 121 (32.4) | 1.86 (1.21–2.85) | < 0.001 |
| Disease duration | 15 (13.27) | 11 (9.25) | 0.97 (0.95–0.99) | < 0.001 |
| TJC | 1.60 (3.43) | 1.74 (3.70) | 1.01 (0.95–1.07) | 0.80 |
| SJC | 0.57 (1.55) | 0.50 (1.51) | 0.95 (0.84–1.08) | 0.45 |
| PatGA | 33.36 (26.70) | 34.53 (27.65) | 1.00 (0.99–1.01) | 0.70 |
| Pain | 31.53 (24.30) | 31.22 (24.71) | 0.99 (0.99–1.01) | 0.73 |
| Fatigue | 37.50 (26.80) | 39.70 (28.70) | 1.00 (0.99–1.01) | 0.36 |
| HAQ | 0.64 (0.60) | 0.67 (0.63) | 1.33 (0.97–1.82) | 0.07 |
| EQ5D | 0.80 (0.15) | 0.78 (0.15) | 0.80 (0.23–2.71) | 0.71 |
| Cardiovascular disease*1 | 61 (31.6) | 172 (46.1) | 1.90 (1.28–2.82) | 0.001 |
Data presented as mean (SD) or n (%) if not noted otherwise
†Logistic regression, controlled for age, gender and disease duration. Data presented as odds ratio (OR) and 95% confidence intervals
TJC, tender joint count (0–28); SJC, swollen joint count (0–28); PatGa, patient global assessment (0–100, best to worst); pain (0–100, best to worst); fatigue (0–100, best to worst); HAQ, Health Assessment Questionnaire (0–3, best to worst); EQ5D, Euroqol Five Dimensions (0–1, worst to best)
*1Includes hypertension, hypercholesterolemia, angina pectoris, myocardial infarction, stroke, vasoconstriction of the legs and ‘other CVDs’
Association between the combined number of unhealthy lifestyle factors (UL) and disease-related factors among the Swedish patients (N = 955)
| < 2 UL | ≥ 2 UL | OR† (CI 95%) | ||
|---|---|---|---|---|
| Age | 65.71 (13.8) | 67.16 (11.71) | 1.01 (0.99–1.02) | 0.082 |
| Gender, men | 122 (23.9) | 137 (30.9) | 1.42 (1.07–1.89) | 0.016 |
| Disease duration | 15.61 (3.88) | 15.48 (3.81) | 0.99 (0.06–1.02) | 0.605 |
| TJC | 5.02 (6.36) | 5.40 (6.79) | 1.01 (0.99–1.03) | 0.336 |
| SJC | 2.74 (4.56) | 3.43 (5.23) | 1.03 (1.00–1.06) | 0.025 |
| PatGA | 2.83 (2.37) | 3.27 (2.48) | 1.08 (1.03–1.14) | 0.004 |
| Pain | 3.17 (2.45) | 3.71 (2.62) | 1.10 (1.04–1.15) | 0.001 |
| Fatigue | 3.79 (2.84) | 4.41 (2.82) | 1.09 (1.04–1.15) | < 0.001 |
| HAQ | 0.45 (0.51) | 0.59 (0.60) | 1.64 (1.28–2.10) | < 0.001 |
| EQ5D | 0.74 (0.22) | 0.68 (0.27) | 0.35 (0.20–0.60) | < 0.001 |
| Cardiovascular disease*1 | 218 (42.7) | 253 (57) | 1.83 (1.40–2.43) | < 0.001 |
| Pulmonary disease*2 | 53 (10.4) | 60 (13.5) | 1.34 (0.90–1.99) | 0.151 |
Data presented as mean (SD) or n (%), if not noted otherwise
†Logistic regression, controlled for age, gender and disease duration. Data presented as odds ratio (OR) and 95% confidence intervals
TJC, tender joint count (0–28); SJC, swollen joint count (0–28); PatGa, patient global assessment (0–10, best to worst); pain (0–10, best to worst); fatigue (0–10, best to worst); HAQ, Health Assessment Questionnaire (0–3, best to worst); EQ5D, Euroqol Five Dimensions (0–1, worst to best)
*1Includes hypertension, hypercholesterolemia, angina pectoris, myocardial infarction, thrombus and stroke
*2Includes asthma, chronic obstructive pulmonary disease and emphysema
|